$TNON
Tenon Medical, Inc. Stock $tnon

$tnon Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024043085 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$901.0K	$719.0K	$433.0K
YoY Change	21.27%	66.05%	509.86%
Cost Of Revenue	$431.0K	$249.0K	$480.0K
YoY Change	-21.49%	-48.13%	74.55%
Gross Profit	$470.0K	$470.0K	-$47.00K
YoY Change	142.27%	-1100.0%	-76.96%
Gross Profit Margin	52.16%	65.37%	-10.85%
Selling, General & Admin	$3.634M	$3.307M	$4.005M
YoY Change	0.53%	-17.43%	205.03%
% of Gross Profit	773.19%	703.62%
Research & Development	$708.0K	$669.0K	$834.0K
YoY Change	-21.42%	-19.78%	48.4%
% of Gross Profit	150.64%	142.34%
Depreciation & Amortization	$86.00K	$100.0K	$25.00K
YoY Change	145.71%	300.0%	150.0%
% of Gross Profit	18.3%	21.28%
Operating Expenses	$4.342M	$3.976M	$4.839M
YoY Change	-3.85%	-17.83%	158.08%
Operating Profit	-$3.872M	-$3.506M	-$4.886M
YoY Change	-10.41%	-28.24%	135.02%
Interest Expense	$39.00K	$34.00K	$56.00K
YoY Change		-39.29%	-120.51%
% of Operating Profit
Other Income/Expense, Net	$46.00K	-$70.00K	$56.00K
YoY Change	24.32%	-225.0%	-5700.0%
Pretax Income	-$3.826M	-$3.576M	-$4.830M
YoY Change	-10.71%	-25.96%	105.27%
Income Tax
% Of Pretax Income
Net Earnings	-$3.826M	-$3.576M	-$4.830M
YoY Change	-10.71%	-25.96%	105.27%
Net Earnings / Revenue	-424.64%	-497.36%	-1115.47%
Basic Earnings Per Share	-$1.02	-$1.25	-$0.43
Diluted Earnings Per Share	-$1.02	-$1.25	-$0.43
COMMON SHARES
Basic Shares Outstanding	3.729M shares	3.727M shares	11.25M
Diluted Shares Outstanding	3.749K shares	2.853K shares	11.24K

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.968M	$4.388M	$4.916M
YoY Change	-68.98%	-10.74%	5.11%
Cash & Equivalents	$1.968M	$4.388M	$3.179M
Short-Term Investments			$1.737M
Other Short-Term Assets	$831.0K	$360.0K	$193.0K
YoY Change	101.21%	86.53%	135.37%
Inventory	$609.0K	$632.0K	$416.0K
Prepaid Expenses		$360.0K	$193.0K
Receivables	$679.0K	$571.0K	$316.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.087M	$5.951M	$5.841M
YoY Change	-48.46%	1.88%	7.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$904.0K	$993.0K	$852.0K
YoY Change	-4.34%	16.55%	-31.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$490.0K	$490.0K	$118.0K
YoY Change	123.74%	315.25%	-74.84%
Total Long-Term Assets	$1.919M	$2.069M	$1.788M
YoY Change	-0.36%	15.72%	3.95%
TOTAL ASSETS
Total Short-Term Assets	$4.087M	$5.951M	$5.841M
Total Long-Term Assets	$1.919M	$2.069M	$1.788M
Total Assets	$6.006M	$8.020M	$7.629M
YoY Change	-39.06%	5.13%	6.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.111M	$266.0K	$928.0K
YoY Change	21.82%	-71.34%	118.35%
Accrued Expenses	$932.0K	$941.0K	$530.0K
YoY Change	-17.52%	77.55%	-55.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.403M	$2.262M	$2.752M
YoY Change	-50.44%	-17.81%	-82.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.771M	$2.134M	$2.403M
YoY Change	-15.1%	-11.19%	186.07%
Total Long-Term Liabilities	$1.771M	$2.134M	$2.403M
YoY Change	-15.1%	-11.19%	186.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.403M	$2.262M	$2.752M
Total Long-Term Liabilities	$1.771M	$2.134M	$2.403M
Total Liabilities	$5.174M	$4.396M	$5.155M
YoY Change	-42.2%	-14.72%	-68.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.48M	-$58.65M	-$44.32M
YoY Change	28.53%	32.32%
Common Stock	$4.000K	$58.97M	$11.00K
YoY Change	-81.82%	536018.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$832.0K	$3.624M	$2.474M
YoY Change
Total Liabilities & Shareholders Equity	$6.006M	$8.020M	$7.629M
YoY Change	-39.06%	5.13%	6.77%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$3.826M	-$3.576M	-$4.830M
YoY Change	-10.71%	-25.96%	105.27%
Depreciation, Depletion And Amortization	$86.00K	$100.0K	$25.00K
YoY Change	145.71%	300.0%	150.0%
Cash From Operating Activities	-$2.420M	-$2.338M	-$3.576M
YoY Change	-23.8%	-34.62%	45.13%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$119.0K	$84.00K
YoY Change	-100.0%	41.67%	-165.63%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$4.753M
YoY Change		-100.0%	7.92%
Cash From Investing Activities	$0.00	-$119.0K	$4.669M
YoY Change	-100.0%	-102.55%	9.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$4.371M	-42.00K
YoY Change	-100.0%	-10507.14%	-22.22%
NET CHANGE
Cash From Operating Activities	-2.420M	-$2.338M	-3.576M
Cash From Investing Activities	0.000	-$119.0K	4.669M
Cash From Financing Activities	0.000	$4.371M	-42.00K
Net Change In Cash	-2.420M	$1.960M	1.050M
YoY Change	-190.98%	86.67%	-40.27%
FREE CASH FLOW
Cash From Operating Activities	-$2.420M	-$2.338M	-$3.576M
Capital Expenditures	$0.00	$119.0K	$84.00K
Free Cash Flow	-$2.420M	-$2.457M	-$3.660M
YoY Change	-26.76%	-32.87%	56.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.30
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41364
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	TENON MEDICAL, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5574718
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	104 Cooper Court
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Gatos
CY2024Q1	dei	Entity Address Country EntityAddressCountry	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95032
CY2024Q1	dei	City Area Code CityAreaCode	(408)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	649-5760
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	TNON
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3729474	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4388000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2428000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	571000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	518000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	632000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	554000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	360000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	389000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	5951000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3889000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	993000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	961000	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	51000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	51000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	586000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646000	usd
CY2024Q1	us-gaap	Deferred Costs DeferredCosts	439000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	798000	usd
CY2024Q1	us-gaap	Assets Assets	8020000	usd
CY2023Q4	us-gaap	Assets Assets	6345000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	266000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	433000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	941000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	808000	usd
CY2024Q1	tnon	Accrued Commissions Current AccruedCommissionsCurrent	792000	usd
CY2023Q4	tnon	Accrued Commissions Current AccruedCommissionsCurrent	470000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	263000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	77000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1173000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2262000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3140000	usd
CY2024Q1	tnon	Accrued Commissions Noncurrent AccruedCommissionsNoncurrent	1774000	usd
CY2023Q4	tnon	Accrued Commissions Noncurrent AccruedCommissionsNoncurrent	1999000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	360000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	428000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	4396000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5567000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3726974	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3726974	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2600311	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2600311	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	58969000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55894000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58649000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55073000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-46000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3624000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	778000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8020000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6345000	usd
CY2024Q1	us-gaap	Revenues Revenues	719000	usd
CY2023Q1	us-gaap	Revenues Revenues	433000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	249000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	480000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	470000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-47000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	669000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	834000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1381000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2026000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1926000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1979000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3976000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4839000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3506000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4886000	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	27000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	56000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	34000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-70000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	56000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3576000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4830000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.3
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2853	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1124	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3576000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4830000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	13000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	46000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3530000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4818000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	778000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1018000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1804000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	-3554000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	46000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3576000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3624000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6252000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1040000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4830000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2474000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3576000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4830000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1018000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1040000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	60000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	55000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	63000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	88000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	78000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-29000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-167000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	378000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	390000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-61000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-54000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2338000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3576000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4753000	usd
CY2024Q1	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	119000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	84000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-119000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4669000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	2437000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1934000	usd
CY2023Q1	tnon	Payments For Deferred Offering Costs PaymentsForDeferredOfferingCosts	42000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4371000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-42000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1960000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1050000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2428000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2129000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4388000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3179000	usd
CY2024Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1186000	usd
CY2024Q1	tnon	Reclassification Of Deferred Offering Costs To Additional Paidin Capital ReclassificationOfDeferredOfferingCostsToAdditionalPaidinCapital	130000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Organization and Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nature of operations</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tenon Medical, Inc. (the “Company”) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran™ SI Joint Fusion System (“the Catamaran System”) that offers a novel, less invasive approach to the sacroiliac joint (the “SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Principles of consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed consolidated financial statements of the Company for the first quarter of 2023 and as of December 31, 2023 include the accounts of its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. In the first quarter of 2024, TTAG was effectively dissolved and, as such, the financial statements for the first quarter of 2024 and as of March 31, 2024 only include the accounts of the Company.</p>
CY2024Q2	us-gaap	Share Price SharePrice	1
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory and stock-based compensation.</p>
CY2023Q4	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1	shares
CY2024Q1	tnon	Percentage Of Valuation Allowance In Deferred Tax Assets PercentageOfValuationAllowanceInDeferredTaxAssets	1	pure
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5190255	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	237437	shares
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1353000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1234000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	360000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	273000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	993000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	961000	usd
CY2024Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	87000	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	25000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	422000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	334000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	519000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	474000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	941000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	808000	usd
CY2024Q1	tnon	Term Of Warrants Expire TermOfWarrantsExpire	P5Y
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	73000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	73000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	586000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	263000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	360000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	428000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	623000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	684000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	228000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	310000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	144000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	682000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	59000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	623000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	74000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	72000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y3M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	tnon	Aggregate Gross Sales Price AggregateGrossSalesPrice	5500000	usd
CY2023Q2	tnon	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.03	pure
CY2024Q1	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	(i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share
CY2024Q1	tnon	Purchase Exceed Amount PurchaseExceedAmount	500000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	100000	shares
CY2024Q1	tnon	Percentage Of Outstanding Shares PercentageOfOutstandingShares	0.0499	pure
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1018000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1040000	usd
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2000000	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2024Q1	tnon	Class Of Warrants Of Rights Grant Date Fair Value Of Warrants ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants	3164
CY2024Q1	tnon	Fair Value Of Offering Warrant FairValueOfOfferingWarrant	1.58
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3
CY2024Q1	tnon	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Daily Return Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDailyReturnRate	0.0518	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1	pure
CY2024Q1	tnon	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Standarddeviation ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStandarddeviation	0.063	pure
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2377000	usd
CY2024Q1	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	98000	usd
CY2024Q1	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	149000	usd
CY2024Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2428000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2023Q1	us-gaap	Interest Expense InterestExpense		usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1124	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2853	shares
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2024Q1	tnon	Payments For Deferred Offering Costs PaymentsForDeferredOfferingCosts		usd
CY2023Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
CY2023Q1	tnon	Reclassification Of Deferred Offering Costs To Additional Paidin Capital ReclassificationOfDeferredOfferingCostsToAdditionalPaidinCapital		usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001560293

Files In Submission

Name	View Source	Status
0001213900-24-043085-index-headers.html	Edgar Link	pending
0001213900-24-043085-index.html	Edgar Link	pending
0001213900-24-043085.txt	Edgar Link	pending
0001213900-24-043085-xbrl.zip	Edgar Link	pending
ea0205750-10q_tenon.htm	Edgar Link	pending
ea020575001ex31-1_tenon.htm	Edgar Link	pending
ea020575001ex31-2_tenon.htm	Edgar Link	pending
ea020575001ex32-1_tenon.htm	Edgar Link	pending
ea020575001ex32-2_tenon.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
ea0205750-10q_tenon_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
tnon-20240331.xsd	Edgar Link	pending
tnon-20240331_def.xml	Edgar Link	unprocessable
tnon-20240331_lab.xml	Edgar Link	unprocessable
tnon-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
tnon-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNON
Tenon Medical, Inc. Stock $tnon

2024 Q2 Form 10-Q Financial Statement

#000121390024043085 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNON Tenon Medical, Inc. Stock $tnon

2024 Q2 Form 10-Q Financial Statement

#000121390024043085 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNON
Tenon Medical, Inc. Stock $tnon